PUMA BIOTECHNOLOGY, INC. Increase (Decrease) in Accounts Receivable
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Increase (Decrease) in Accounts Receivable of -$19.59 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $7.73M, a 1956.12% increase year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$27.32M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $20.09M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $7.44M, a 71.91% decline year-over-year.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for fiscal 2025 was $21.28M.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for fiscal 2024 was -$16.34M, a 295.33% decline from fiscal 2023.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for fiscal 2023 was $8.37M, a 6.95% increase from fiscal 2022.
- PUMA BIOTECHNOLOGY, INC. increase (decrease) in accounts receivable for fiscal 2022 was $7.82M, a 30.77% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$19.59M 10-Q · filed 2026-08-06 | $495.00K derived: sum of 3 quarters · filed 2026-08-06 | $7.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$27.32M 10-Q · filed 2026-05-07 | -$7.24M derived: sum of 2 quarters · filed 2026-05-07 | $206.00K derived: sum of 3 quarters · filed 2026-05-07 | $582.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $20.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.53M derived: sum of 2 quarters · filed 2026-02-26 | $27.91M derived: sum of 3 quarters · filed 2026-08-06 | $21.28M 10-K · filed 2026-02-26 |
| 2025-09-30 | $7.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.82M derived: sum of 2 quarters · filed 2026-08-06 | $1.19M 10-Q · filed 2025-11-06 | -$21.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $376.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$6.25M 10-Q · filed 2026-08-06 | -$29.28M derived: sum of 3 quarters · filed 2026-08-06 | -$2.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$6.63M 10-Q · filed 2026-05-07 | -$29.66M derived: sum of 2 quarters · filed 2026-05-07 | -$3.17M derived: sum of 3 quarters · filed 2026-05-07 | $172.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$23.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.46M derived: sum of 2 quarters · filed 2026-02-26 | $6.80M derived: sum of 3 quarters · filed 2026-02-26 | -$16.34M 10-K · filed 2026-02-26 |
| 2024-09-30 | $26.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $29.83M derived: sum of 2 quarters · filed 2025-11-06 | $6.68M 10-Q · filed 2025-11-06 | $25.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $3.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$19.80M 10-Q · filed 2025-08-07 | -$575.00K derived: sum of 3 quarters · filed 2026-02-26 | -$2.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$23.14M 10-Q · filed 2025-05-08 | -$3.91M derived: sum of 2 quarters · filed 2026-02-26 | -$6.23M derived: sum of 3 quarters · filed 2026-02-26 | -$5.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $19.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $16.91M derived: sum of 2 quarters · filed 2026-02-26 | $17.55M derived: sum of 3 quarters · filed 2026-02-26 | $8.37M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.68M derived: sum of 2 quarters · filed 2024-11-07 | -$10.86M 10-Q · filed 2024-11-07 | $1.46M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $640.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$8.55M 10-Q · filed 2024-08-01 | $3.77M derived: sum of 3 quarters · filed 2025-02-27 | -$2.18M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$9.19M 10-Q · filed 2024-05-02 | $3.13M derived: sum of 2 quarters · filed 2025-02-27 | -$2.82M derived: sum of 3 quarters · filed 2025-02-27 | $4.13M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $12.32M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $6.36M derived: sum of 2 quarters · filed 2025-02-27 | $13.31M derived: sum of 3 quarters · filed 2025-02-27 | $7.82M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$5.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $991.00K derived: sum of 2 quarters · filed 2023-11-02 | -$4.50M 10-Q · filed 2023-11-02 | $4.23M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $6.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $1.46M 10-Q · filed 2023-08-03 | $10.19M derived: sum of 3 quarters · filed 2024-02-29 | $3.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$5.49M 10-Q · filed 2023-05-04 | $3.24M derived: sum of 2 quarters · filed 2024-02-29 | -$3.51M derived: sum of 3 quarters · filed 2024-02-29 | -$119.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $8.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $1.98M derived: sum of 2 quarters · filed 2024-02-29 | $5.37M derived: sum of 3 quarters · filed 2024-02-29 | $5.98M 10-K · filed 2024-02-29 |
| 2021-09-30 | -$6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$3.36M derived: sum of 2 quarters · filed 2022-11-03 | -$2.74M 10-Q · filed 2022-11-03 | -$3.34M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $3.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $4.01M 10-Q · filed 2022-08-04 | $3.41M derived: sum of 3 quarters · filed 2023-03-02 | $6.56M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $615.00K 10-Q · filed 2022-05-05 | $21.00K derived: sum of 2 quarters · filed 2023-03-02 | $3.17M derived: sum of 3 quarters · filed 2023-03-02 | -$4.38M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | -$594.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $2.56M derived: sum of 2 quarters · filed 2023-03-02 | -$5.00M derived: sum of 3 quarters · filed 2023-03-02 | -$2.35M 10-K · filed 2023-03-02 |
| 2020-09-30 | $3.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$4.41M derived: sum of 2 quarters · filed 2021-11-04 | -$1.76M 10-Q · filed 2021-11-04 | -$45.00K derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | -$7.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$4.91M 10-Q · filed 2021-08-05 | -$3.19M derived: sum of 3 quarters · filed 2022-03-03 | -$1.36M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $2.65M 10-Q · filed 2021-05-06 | $4.36M derived: sum of 2 quarters · filed 2022-03-03 | $6.20M derived: sum of 3 quarters · filed 2022-03-03 | -$49.44M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $3.55M derived: sum of 2 quarters · filed 2022-03-03 | -$52.09M derived: sum of 3 quarters · filed 2022-03-03 | $8.12M 10-K · filed 2022-03-03 |
| 2019-09-30 | $1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$53.80M derived: sum of 2 quarters · filed 2020-11-05 | $6.41M 10-Q · filed 2020-11-05 | $7.43M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$55.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $4.57M 10-Q · filed 2020-08-06 | $5.60M derived: sum of 3 quarters · filed 2021-03-01 | $4.00M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $60.21M 10-Q · filed 2020-05-07 | $61.23M derived: sum of 2 quarters · filed 2021-03-01 | $59.64M derived: sum of 3 quarters · filed 2021-03-01 | $64.67M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$570.00K derived: sum of 2 quarters · filed 2021-03-01 | $4.46M derived: sum of 3 quarters · filed 2021-03-01 | $11.10M 10-K · filed 2021-03-01 |
| 2018-09-30 | -$1.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $3.44M derived: sum of 2 quarters · filed 2019-11-07 | $10.08M 10-Q · filed 2019-11-07 | $15.86M derived: sum of 4 quarters · filed 2020-02-28 |
| 2018-06-30 | $5.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $11.67M 10-Q · filed 2019-08-09 | $17.45M derived: sum of 3 quarters · filed 2020-02-28 | |
| 2018-03-31 | $6.64M 10-Q · filed 2019-05-10 | $12.42M derived: sum of 2 quarters · filed 2020-02-28 | ||
| 2017-12-31 | $5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $9.67M 10-K · filed 2020-02-28 | ||
| 2017-09-30 | $3.89M 10-Q · filed 2018-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |